Investment Analysts’ Recent Ratings Changes for Avantor (AVTR)

Several brokerages have updated their recommendations and price targets on shares of Avantor (NYSE: AVTR) in the last few weeks:

• 2/10/2025 – Avantor had its price target lowered by analysts at Morgan Stanley from $27.00 to $25.00. They now have an “overweight” rating on the stock.
• 2/10/2025 – Avantor had its price target lowered by analysts at Wells Fargo & Company from $28.00 to $25.00. They now have an “overweight” rating on the stock.
• 2/10/2025 – Avantor had its price target lowered by analysts at Barclays PLC from $26.00 to $23.00. They now have an “overweight” rating on the stock.
• 2/10/2025 – Avantor had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $24.00 price target on the stock, down previously from $26.00.
• 2/10/2025 – Avantor had its price target lowered by analysts at Royal Bank of Canada from $33.00 to $31.00. They now have an “outperform” rating on the stock.
• 2/10/2025 – Avantor had its price target lowered by analysts at Stifel Nicolaus from $28.00 to $26.00. They now have a “buy” rating on the stock.
• 2/3/2025 – Avantor had its price target raised by analysts at Barclays PLC from $25.00 to $26.00. They now have an “overweight” rating on the stock.
• 1/21/2025 – Avantor had its price target lowered by analysts at Raymond James from $29.00 to $26.00. They now have an “outperform” rating on the stock.
• 1/17/2025 – Avantor had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $25.00 price target on the stock, down previously from $29.00.

Avantor Trading Down 1.9 %

AVTR opened at $17.22 on Thursday. The stock has a market capitalization of $11.73 billion, a price-to-earnings ratio of 16.56, a P/E/G ratio of 1.55 and a beta of 1.28. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54. Avantor, Inc. has a twelve month low of $17.14 and a twelve month high of $28.00. The company has a 50-day simple moving average of $20.69 and a 200 day simple moving average of $22.79.

Avantor (NYSE:AVTR) last announced its earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter in the prior year, the firm posted $0.22 EPS. Analysts predict that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Avantor

Several large investors have recently modified their holdings of the business. Louisiana State Employees Retirement System lifted its position in Avantor by 0.3% in the 4th quarter. Louisiana State Employees Retirement System now owns 188,900 shares of the company’s stock worth $3,980,000 after buying an additional 500 shares during the last quarter. Hantz Financial Services Inc. increased its position in shares of Avantor by 2.1% during the third quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock valued at $644,000 after acquiring an additional 503 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Avantor by 6.9% during the fourth quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock valued at $170,000 after buying an additional 522 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Avantor by 0.5% during the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock valued at $2,103,000 after purchasing an additional 542 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Avantor by 10.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,257 shares of the company’s stock worth $132,000 after purchasing an additional 592 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.